Reametrix, a Bangalore-based company that provides basic research and assay development services to biotechnology and pharmaceutical companies, is scouting for strategic partners to take TriTstat, a critical diagnostic product for managing HIV patients, to the global markets.
Reametrix, which was incorporated five years ago with the purpose of ‘reverse innovation’, develops products to address human diagnostics in the domestic market.
“India will be the incubation point for our products, which will be then rolled out in the global markets. We are in discussion with a few strategic partners for this purpose and expect to seal deals with them in the next 12 months,” Bala S Manian, founder of Reametrix, told Business Standard on the sidelines of International Knowledge Millennium Conference 2009.
Manian, who holds more than 30 patents for electro-optical systems, said the company had developed TriTstat for drying reagents and chemicals, eliminating the cold chain. The product combines, formulates and unifies the chemicals, which is of interest to the West as the US Food and Drug Administration (US FDA)-approved product eliminates labour costs too, he added.
“We are initially eyeing the African market and our product already has validation in Canada. We are now in the process of expanding TriTstat to veterinary diagnostics,” Manian said, adding the company was also bidding for government tenders.
Reametrix has a 20,000-sft facility in Bangalore.
